H. Lundbeck stock
HLUN-B.COCPHH. Lundbeck A/S, HealthcareISIN DK0061804770
80Score 80 out of 100, Strong
Price and trend
83 / 100
Price history
+32% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 36% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 4.4% below its 52-week high. Largest decline in 4 years: 44% (October 2024 to April 2025).
Chart figures for advanced users
- SMA 50$7.14
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.48
- The lowest closing price of the last twelve months.
- Resistance$9.11
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- H. Lundbeck A/S belongs to the Drug Manufacturers (Specialty & Generic) industry (Denmark) and, with a market value of $8.64B, is number 30 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.61B (up 10.7% year on year) and earnings of $473.16M (up 1.6%).
- For fiscal 2026, analysts expect on average revenue of $3.86B (up 6.8%) and adjusted earnings per share of $4.69 (up 861.3%).
Show more
- MEQIRI Score 80 out of 100 (Strong): rank 21 of 702 in Healthcare, median 53.
- The P/E is 14.4 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 13.5).
- Our model puts fair value at $14.56, with the price 40% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 40% below the fair value of $14.56.Valuation 93
- Earnings per share growingUp 18% a year since 2021.Growth 71
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 93
Weaknesses
- DilutionShare count up 25% since 2021.Capital allocation 54
Its standout strengths are fundamentals and valuation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 79 to 80.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $11.20 and expensive above $20.79 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $17.67 (cash-flow model) and $11.44 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $13.05, at 6.2% it would be $16.82.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.2% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 80%, operating 26%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Feb 2027in 89 days
- Last reported
- 10 Nov 2026EPS reported $0.19 (expected $0.16)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 578.0% since 15 Oct 2026.
- Earnings per share
- $4.69+578.0%
- Revenue
- $3.86B+0.5%
- Earnings per share
- $4.70+574.6%
- Revenue
- $3.88B+0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −7.3%Full-year guidance confirmed after the increase in the first quarter; the company is tracking toward the upper end of its ranges.
“So overall, the strong first half supports the guidance increase and narrowing we made at Q1 and gives us confidence that we are currently tracking towards the upper end of our full year ranges.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 19 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at H. Lundbeck
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 80
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Aurobindo PharmaAUROPHARMA.NS $11.05B67
- LupinLUPIN.NS $9.79B76
- Eisai4523.T $9.14B62
- Shanghai Fosun Pharmaceutical (Group)600196.SS $9.13B47
- Krka, d. d.KRK.WA $8.43B76
- Glenmark PharmaceuticalsGLENMARK.NS $7.98B74
- AlkermesALKS $7.89B53
- Amneal PharmaceuticalsAMRX $7.56B58
ETFs that hold H. Lundbeck
Held by 21 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.27% | 0.23% | €321.86M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.22% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.20% | 0.40% | €813.42M |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.15% | 0.30% | €813.64M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.13% | 0.30% | €3.45B |
| Invesco RAFI Europe Fundamental Value UCITS ETF6PSC | 0.03% | 0.39% | €37.66M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.